CENTESSA PHARMACEUTICALS-ADR
Centessa Pharmaceuticals (CNTA) is a clinical-stage biotechnology company that operates as a portfolio of independent, specialist teams advancing a range of therapeutic candidates across multiple disease areas. With a market capitalisation of about $3.05 billion, Centessa aims to accelerate early- and mid-stage programmes by providing centralised services while allowing individual research teams to retain scientific focus. For investors this means exposure to a diversified set of development assets rather than a single product bet, but the company remains subject to typical biotech risks: clinical trial outcomes, regulatory decisions, long development timelines and capital needs. Centessa currently does not pay dividends and is likely to show higher share-price volatility than established pharmaceutical companies. This summary is educational only and not personal financial advice — potential investors should assess their own risk tolerance, time horizon and consult a qualified adviser before investing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Centessa Pharmaceuticals stock, indicating confidence in its future growth potential.
Financial Health
Centessa Pharmaceuticals is generating modest revenue and cash flow, indicating some financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CNTA
Hematology Stocks | BTK Inhibitor FDA Breakthrough
Following the FDA's approval of Sanofi's Wayrilz, the first BTK inhibitor for a rare blood disorder, a new investment opportunity has emerged. This theme focuses on innovative pharmaceutical companies developing next-generation treatments for rare hematological diseases, a market poised for significant growth.
Published: August 30, 2025
Explore BasketThe Global Weight-Loss Drug Price Shift
Eli Lilly's significant price hike for Mounjaro in the UK, driven by U.S. political pressure, highlights a new global pricing strategy for blockbuster drugs. This creates a potential opportunity for competitors in the booming weight-loss market as patients and providers may seek more affordable alternatives.
Published: August 15, 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: August 5, 2025
Explore BasketChina's Biopharma Innovators: The Next Global Partnership Wave
Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Published: July 28, 2025
Explore BasketNew Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: July 3, 2025
Explore BasketThe Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: July 2, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Portfolio Approach
Centessa pools many development teams under one umbrella, offering diversified exposure to multiple programmes — though individual trial results can still move the stock sharply.
Clinical Catalysts
Share performance can hinge on trial readouts and regulatory milestones, which may create swings in value; monitor timelines and data releases closely.
Research Partnerships
Centessa uses centralised services and collaborations to advance assets; partnerships can de‑risk programmes but outcomes and funding needs vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
